HCW Biologics Ownership
| HCWB Stock | USD 4.32 0.15 3.36% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 38.8 M | Current Value 44.7 M | Avarage Shares Outstanding 34.5 M | Quarterly Volatility 4.2 M |
HCW Stock Ownership Analysis
About 30.0% of the company shares are held by company insiders. The company recorded a loss per share of 24.8. HCW Biologics had not issued any dividends in recent years. The entity had 1:40 split on the 11th of April 2025. HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company was incorporated in 2018 and is headquartered in Miramar, Florida. Hcw Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people. To learn more about HCW Biologics call Hing Wong at 954 842 2024 or check out https://www.hcwbiologics.com.Besides selling stocks to institutional investors, HCW Biologics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different HCW Biologics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align HCW Biologics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
HCW Biologics Quarterly Liabilities And Stockholders Equity |
|
HCW Biologics Insider Trades History
About 30.0% of HCW Biologics are currently held by insiders. Unlike HCW Biologics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against HCW Biologics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of HCW Biologics' insider trades
HCW Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as HCW Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading HCW Biologics backward and forwards among themselves. HCW Biologics' institutional investor refers to the entity that pools money to purchase HCW Biologics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2025-03-31 | 1 K | Bank Of America Corp | 2025-03-31 | 210 | Tower Research Capital Llc | 2025-03-31 | 32.0 | Hightower Advisors, Llc | 2025-03-31 | 0.0 | Bridgeway Capital Management, Llc | 2025-03-31 | 0.0 | Ubs Group Ag | 2024-12-31 | 0.0 | Renaissance Technologies Corp | 2025-03-31 | 0.0 | Armistice Capital, Llc | 2025-03-31 | 0.0 | Two Sigma Investments Llc | 2025-03-31 | 0.0 | Honkamp Krueger Financial Services Inc | 2025-03-31 | 279.5 K | Vanguard Group Inc | 2025-03-31 | 243.2 K |
HCW Biologics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific HCW Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on HCW Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases HCW Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
HCW Biologics Outstanding Bonds
HCW Biologics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. HCW Biologics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most HCW bonds can be classified according to their maturity, which is the date when HCW Biologics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| HSBC HLDGS PLC Corp BondUS404280AE90 | View | |
| HSBC HLDGS PLC Corp BondUS404280AF65 | View | |
| HSBC HLDGS PLC Corp BondUS404280AG49 | View | |
| HSBC HLDGS PLC Corp BondUS404280AM17 | View | |
| HSBC HLDGS PLC Corp BondUS404280AH22 | View | |
| HSBC HLDGS PLC Corp BondUS404280AJ87 | View | |
| HSBC HLDGS PLC Corp BondUS404280AU33 | View | |
| HSBC HLDGS PLC Corp BondUS404280AW98 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HCW Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (24.80) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.